| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Polyomavirus Infections | 11 | 2019 | 156 | 2.47 | Why? |
| BK Virus | 9 | 2019 | 135 | 2.08 | Why? |
| Tumor Virus Infections | 6 | 2019 | 127 | 1.06 | Why? |
| Cytomegalovirus | 4 | 2018 | 600 | 0.84 | Why? |
| Polyomaviridae | 1 | 2018 | 8 | 0.75 | Why? |
| Antigens, Viral, Tumor | 1 | 2018 | 7 | 0.75 | Why? |
| Deoxyribonucleases | 1 | 2018 | 34 | 0.74 | Why? |
| Gene Rearrangement | 1 | 2018 | 84 | 0.72 | Why? |
| Respiratory Tract Infections | 7 | 2021 | 6817 | 0.67 | Why? |
| Cytomegalovirus Infections | 3 | 2018 | 667 | 0.66 | Why? |
| Biodiversity | 1 | 2019 | 546 | 0.60 | Why? |
| Community-Acquired Infections | 3 | 2019 | 2328 | 0.60 | Why? |
| Models, Genetic | 1 | 2018 | 434 | 0.60 | Why? |
| Enterovirus | 1 | 2018 | 402 | 0.53 | Why? |
| Kidney Transplantation | 11 | 2019 | 5397 | 0.53 | Why? |
| Kidney Diseases | 6 | 2019 | 1434 | 0.50 | Why? |
| Enterovirus Infections | 1 | 2018 | 404 | 0.50 | Why? |
| Gene Expression Regulation, Viral | 2 | 2018 | 925 | 0.49 | Why? |
| Gastroenteritis | 1 | 2018 | 489 | 0.49 | Why? |
| Organ Transplantation | 4 | 2020 | 2616 | 0.45 | Why? |
| Switzerland | 10 | 2021 | 2738 | 0.44 | Why? |
| Transplant Recipients | 7 | 2020 | 4982 | 0.43 | Why? |
| DNA, Viral | 5 | 2019 | 2521 | 0.43 | Why? |
| Virus Diseases | 3 | 2019 | 3779 | 0.43 | Why? |
| Viruses | 2 | 2021 | 2238 | 0.39 | Why? |
| JC Virus | 2 | 2019 | 39 | 0.38 | Why? |
| Patient Care | 1 | 2020 | 1664 | 0.37 | Why? |
| Cystitis | 2 | 2018 | 45 | 0.32 | Why? |
| Communicable Diseases, Emerging | 1 | 2020 | 2523 | 0.30 | Why? |
| Living Donors | 3 | 2019 | 652 | 0.28 | Why? |
| Viral Load | 7 | 2020 | 15850 | 0.27 | Why? |
| Genetic Variation | 1 | 2018 | 3919 | 0.26 | Why? |
| Genome, Viral | 3 | 2021 | 13157 | 0.24 | Why? |
| Viremia | 3 | 2018 | 1020 | 0.24 | Why? |
| Coinfection | 2 | 2020 | 6820 | 0.22 | Why? |
| Practice Guidelines as Topic | 4 | 2020 | 15421 | 0.22 | Why? |
| MicroRNAs | 3 | 2018 | 1787 | 0.21 | Why? |
| Toxoplasmosis, Congenital | 1 | 2018 | 10 | 0.19 | Why? |
| Pregnancy Complications, Parasitic | 1 | 2018 | 23 | 0.19 | Why? |
| Virus Replication | 5 | 2020 | 14331 | 0.19 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.19 | Why? |
| Liver Transplantation | 3 | 2020 | 2864 | 0.19 | Why? |
| Antibodies, Protozoan | 1 | 2018 | 121 | 0.18 | Why? |
| Urothelium | 1 | 2018 | 34 | 0.18 | Why? |
| DNA-Directed DNA Polymerase | 1 | 2018 | 47 | 0.18 | Why? |
| Parasites | 1 | 2018 | 39 | 0.18 | Why? |
| Nephritis | 1 | 2018 | 39 | 0.18 | Why? |
| Immunosuppressive Agents | 7 | 2020 | 6331 | 0.18 | Why? |
| HIV Core Protein p24 | 1 | 2017 | 48 | 0.18 | Why? |
| Postoperative Complications | 5 | 2020 | 5861 | 0.17 | Why? |
| Virus Physiological Phenomena | 1 | 2019 | 155 | 0.17 | Why? |
| Neoplasms | 3 | 2021 | 17251 | 0.17 | Why? |
| HIV-2 | 1 | 2017 | 92 | 0.17 | Why? |
| AIDS Serodiagnosis | 1 | 2017 | 64 | 0.17 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.16 | Why? |
| Pulmonary Disease, Chronic Obstructive | 3 | 2019 | 3832 | 0.16 | Why? |
| Bronchoalveolar Lavage | 1 | 2020 | 603 | 0.16 | Why? |
| Immune Reconstitution | 1 | 2017 | 48 | 0.16 | Why? |
| Muscarinic Antagonists | 1 | 2018 | 176 | 0.16 | Why? |
| Adrenergic beta-2 Receptor Agonists | 1 | 2018 | 142 | 0.16 | Why? |
| Multiplex Polymerase Chain Reaction | 2 | 2021 | 1439 | 0.15 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.15 | Why? |
| Bone and Bones | 1 | 2018 | 235 | 0.15 | Why? |
| Neonatal Screening | 1 | 2018 | 285 | 0.15 | Why? |
| Ritonavir | 2 | 2020 | 4212 | 0.15 | Why? |
| Liver Failure | 1 | 2018 | 266 | 0.14 | Why? |
| Fetal Blood | 1 | 2018 | 573 | 0.14 | Why? |
| Crowding | 1 | 2021 | 731 | 0.14 | Why? |
| Evidence-Based Practice | 1 | 2020 | 693 | 0.14 | Why? |
| Chemokine CXCL10 | 1 | 2018 | 565 | 0.13 | Why? |
| Metagenomics | 1 | 2019 | 823 | 0.13 | Why? |
| Molecular Diagnostic Techniques | 2 | 2021 | 4239 | 0.13 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.12 | Why? |
| Paramyxovirinae | 1 | 2012 | 49 | 0.12 | Why? |
| Humans | 47 | 2021 | 930598 | 0.12 | Why? |
| Prospective Studies | 12 | 2021 | 43301 | 0.12 | Why? |
| Opportunistic Infections | 1 | 2019 | 602 | 0.12 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.12 | Why? |
| Oropharynx | 1 | 2020 | 1581 | 0.12 | Why? |
| Exosomes | 1 | 2018 | 567 | 0.12 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.11 | Why? |
| HIV | 1 | 2019 | 1116 | 0.11 | Why? |
| Hematopoietic Stem Cell Transplantation | 2 | 2018 | 2426 | 0.11 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 952 | 0.11 | Why? |
| HIV Antibodies | 1 | 2017 | 776 | 0.11 | Why? |
| Urinary Bladder Neoplasms | 1 | 2018 | 614 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.11 | Why? |
| Infant, Newborn | 4 | 2020 | 23105 | 0.11 | Why? |
| Child, Preschool | 6 | 2020 | 36283 | 0.10 | Why? |
| Betacoronavirus | 8 | 2020 | 204454 | 0.10 | Why? |
| RNA, Viral | 6 | 2020 | 32276 | 0.10 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.10 | Why? |
| Metapneumovirus | 1 | 2012 | 465 | 0.10 | Why? |
| Male | 26 | 2021 | 367725 | 0.10 | Why? |
| Adult | 19 | 2021 | 244371 | 0.10 | Why? |
| Sequence Analysis, DNA | 1 | 2018 | 2830 | 0.09 | Why? |
| Mutation | 2 | 2021 | 12376 | 0.09 | Why? |
| Middle Aged | 19 | 2021 | 270681 | 0.09 | Why? |
| Biomarkers, Tumor | 1 | 2018 | 1314 | 0.09 | Why? |
| Respiratory Syncytial Viruses | 1 | 2012 | 612 | 0.09 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.09 | Why? |
| Female | 23 | 2021 | 380317 | 0.09 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.09 | Why? |
| Papillomavirus Infections | 1 | 2017 | 861 | 0.09 | Why? |
| Tissue Donors | 1 | 2018 | 1679 | 0.09 | Why? |
| Nucleocapsid Proteins | 1 | 2020 | 3120 | 0.09 | Why? |
| Bacterial Infections | 2 | 2019 | 2229 | 0.09 | Why? |
| Viral Envelope Proteins | 1 | 2020 | 3539 | 0.09 | Why? |
| Lung Transplantation | 1 | 2019 | 1554 | 0.09 | Why? |
| Plasma | 1 | 2018 | 1809 | 0.09 | Why? |
| HIV Infections | 3 | 2019 | 11620 | 0.09 | Why? |
| Infant | 3 | 2020 | 30274 | 0.09 | Why? |
| Leukemia | 1 | 2012 | 598 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.08 | Why? |
| Nasopharynx | 3 | 2020 | 10224 | 0.08 | Why? |
| Dyspnea | 1 | 2020 | 3847 | 0.08 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.08 | Why? |
| Rhinovirus | 1 | 2012 | 979 | 0.08 | Why? |
| Anti-HIV Agents | 1 | 2019 | 2209 | 0.08 | Why? |
| Polyomavirus | 1 | 2006 | 37 | 0.08 | Why? |
| Prevalence | 5 | 2019 | 25773 | 0.08 | Why? |
| Vitamin D | 2 | 2018 | 2904 | 0.08 | Why? |
| Lung Diseases | 1 | 2019 | 2361 | 0.07 | Why? |
| Allografts | 2 | 2019 | 761 | 0.07 | Why? |
| Immunocompromised Host | 5 | 2020 | 5150 | 0.07 | Why? |
| Graft Rejection | 3 | 2018 | 1766 | 0.07 | Why? |
| Antiviral Agents | 6 | 2021 | 41703 | 0.07 | Why? |
| Aged | 13 | 2021 | 215776 | 0.07 | Why? |
| Antineoplastic Agents | 1 | 2020 | 3550 | 0.07 | Why? |
| HEK293 Cells | 1 | 2018 | 8394 | 0.07 | Why? |
| Child | 5 | 2020 | 70012 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Adrenal Cortex Hormones | 2 | 2018 | 6537 | 0.07 | Why? |
| Aged, 80 and over | 5 | 2020 | 88759 | 0.06 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.06 | Why? |
| Adolescent | 5 | 2020 | 86841 | 0.06 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.06 | Why? |
| Pandemics | 10 | 2020 | 389249 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Drug Resistance, Viral | 2 | 2019 | 1083 | 0.06 | Why? |
| Glomerular Filtration Rate | 2 | 2018 | 1262 | 0.06 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2019 | 5164 | 0.06 | Why? |
| Immunoassay | 1 | 2017 | 4485 | 0.06 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.05 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.05 | Why? |
| Germany | 3 | 2021 | 9196 | 0.05 | Why? |
| Follow-Up Studies | 4 | 2020 | 17020 | 0.05 | Why? |
| Retrospective Studies | 7 | 2020 | 105322 | 0.05 | Why? |
| Epidemics | 1 | 2020 | 6407 | 0.05 | Why? |
| Viral Proteins | 1 | 2018 | 7370 | 0.05 | Why? |
| Diagnostic Tests, Routine | 2 | 2021 | 2643 | 0.05 | Why? |
| Toxoplasma | 1 | 2018 | 61 | 0.05 | Why? |
| COS Cells | 1 | 2018 | 157 | 0.05 | Why? |
| Procollagen | 1 | 2018 | 29 | 0.05 | Why? |
| Cell Transformation, Viral | 1 | 2018 | 21 | 0.05 | Why? |
| Microscopy, Electron, Transmission | 1 | 2020 | 605 | 0.05 | Why? |
| Toxoplasmosis | 1 | 2018 | 59 | 0.04 | Why? |
| Collagen Type I | 1 | 2018 | 56 | 0.04 | Why? |
| Bone Remodeling | 1 | 2018 | 59 | 0.04 | Why? |
| Placebo Effect | 1 | 2018 | 108 | 0.04 | Why? |
| Adenovirus Infections, Human | 1 | 2019 | 145 | 0.04 | Why? |
| Infectious Disease Medicine | 1 | 2021 | 311 | 0.04 | Why? |
| Parathyroid Hormone | 1 | 2018 | 98 | 0.04 | Why? |
| Parvoviridae Infections | 1 | 2019 | 222 | 0.04 | Why? |
| United Kingdom | 1 | 2018 | 18046 | 0.04 | Why? |
| Virus Assembly | 1 | 2020 | 438 | 0.04 | Why? |
| Immediate-Early Proteins | 1 | 2017 | 44 | 0.04 | Why? |
| Phosphates | 1 | 2018 | 135 | 0.04 | Why? |
| Poisson Distribution | 1 | 2018 | 348 | 0.04 | Why? |
| Metagenome | 1 | 2019 | 268 | 0.04 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.04 | Why? |
| Urinary Bladder | 1 | 2018 | 170 | 0.04 | Why? |
| Isoantibodies | 1 | 2018 | 134 | 0.04 | Why? |
| Time Factors | 4 | 2021 | 31397 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2018 | 5440 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Paramyxoviridae Infections | 1 | 2019 | 364 | 0.04 | Why? |
| Transplants | 1 | 2017 | 136 | 0.04 | Why? |
| Finland | 1 | 2018 | 671 | 0.04 | Why? |
| Urine | 1 | 2018 | 469 | 0.04 | Why? |
| Graft Survival | 1 | 2018 | 587 | 0.04 | Why? |
| Drug Therapy, Combination | 2 | 2020 | 7268 | 0.04 | Why? |
| Transplantation, Homologous | 1 | 2018 | 757 | 0.04 | Why? |
| Antibodies, Viral | 2 | 2018 | 51949 | 0.04 | Why? |
| Bone Density | 1 | 2018 | 335 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.03 | Why? |
| Neoplasm Metastasis | 1 | 2018 | 682 | 0.03 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2021 | 9893 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2019 | 1654 | 0.03 | Why? |
| Withholding Treatment | 1 | 2020 | 798 | 0.03 | Why? |
| Antibody Formation | 2 | 2018 | 4038 | 0.03 | Why? |
| Picornaviridae Infections | 1 | 2019 | 544 | 0.03 | Why? |
| Societies, Medical | 2 | 2021 | 6907 | 0.03 | Why? |
| Hematology | 1 | 2021 | 649 | 0.03 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| HeLa Cells | 1 | 2017 | 1303 | 0.03 | Why? |
| Pregnancy Complications, Infectious | 1 | 2019 | 11559 | 0.03 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.03 | Why? |
| Respiratory Function Tests | 1 | 2019 | 1755 | 0.03 | Why? |
| Virion | 1 | 2020 | 1444 | 0.03 | Why? |
| False Positive Reactions | 1 | 2017 | 1338 | 0.03 | Why? |
| United States | 1 | 2019 | 46150 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.03 | Why? |
| Seroepidemiologic Studies | 2 | 2018 | 10017 | 0.03 | Why? |
| Fractures, Bone | 1 | 2018 | 487 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2018 | 1647 | 0.03 | Why? |
| Europe | 2 | 2019 | 12702 | 0.03 | Why? |
| Animals | 2 | 2018 | 78931 | 0.03 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1014 | 0.03 | Why? |
| Biomarkers | 3 | 2020 | 23361 | 0.03 | Why? |
| Comorbidity | 3 | 2020 | 34796 | 0.03 | Why? |
| Cost-Benefit Analysis | 1 | 2021 | 2259 | 0.03 | Why? |
| Regression Analysis | 1 | 2018 | 2484 | 0.03 | Why? |
| Mass Screening | 2 | 2021 | 8005 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2019 | 1138 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.02 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2019 | 1234 | 0.02 | Why? |
| Risk Factors | 4 | 2019 | 71621 | 0.02 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.02 | Why? |
| Registries | 2 | 2019 | 12327 | 0.02 | Why? |
| Homosexuality, Male | 1 | 2017 | 1158 | 0.02 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.02 | Why? |
| Health Care Surveys | 1 | 2017 | 2942 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2021 | 3228 | 0.02 | Why? |
| Hematologic Neoplasms | 1 | 2021 | 2105 | 0.02 | Why? |
| Leukocytes, Mononuclear | 1 | 2017 | 2115 | 0.02 | Why? |
| Peptide Fragments | 1 | 2018 | 2075 | 0.02 | Why? |
| Reagent Kits, Diagnostic | 1 | 2017 | 2149 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2019 | 6543 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2018 | 3567 | 0.02 | Why? |
| Survival Analysis | 1 | 2020 | 7592 | 0.02 | Why? |
| Pregnancy | 2 | 2019 | 23879 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Peptides | 1 | 2018 | 2513 | 0.02 | Why? |
| Survival Rate | 1 | 2020 | 9206 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2020 | 6740 | 0.02 | Why? |
| Vitamin D Deficiency | 1 | 2018 | 1782 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Medical Oncology | 1 | 2021 | 3826 | 0.02 | Why? |
| Serologic Tests | 1 | 2018 | 4359 | 0.02 | Why? |
| Kidney | 1 | 2018 | 3648 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Hemorrhage | 1 | 2015 | 3013 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Coronavirus | 1 | 2012 | 18339 | 0.02 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 7868 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| RNA, Messenger | 1 | 2017 | 5131 | 0.01 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.01 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Treatment Outcome | 2 | 2019 | 51732 | 0.01 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 11367 | 0.01 | Why? |
| Age Factors | 1 | 2019 | 21039 | 0.01 | Why? |
| Cohort Studies | 1 | 2021 | 36005 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2018 | 11041 | 0.01 | Why? |
| Prognosis | 1 | 2020 | 32490 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Risk Assessment | 1 | 2019 | 25439 | 0.01 | Why? |
| Influenza, Human | 1 | 2019 | 10779 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2020 | 48226 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2017 | 53120 | 0.01 | Why? |